AstraZeneca Pharma India to Launch Breast Cancer Drug Datverzo in Nov'26
AstraZeneca Pharma India Ltd 路 Others (Uncategorized) 路 07 Nov 2026, 5:49 pm
AstraZeneca Pharma India to Launch Breast Cancer Drug Datverzo in Nov'26 AstraZeneca Pharma India Limited announced it will launch Datopotamab Deruxtecan (brand name: Datverzo) in India in Nov'26, following import and market permissions received from the DCGI in Dec'25. Datverzo is approved for adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer who have undergone prior endocrine-based therapy and chemotherapy.
Original exchange filing (PDF)
More announcements from AstraZeneca Pharma India Ltd
- Please find the enclosed document of the Company as per the captioned subject. This is being resubmitted as the weblink was not correctly re-directing to the relevant web page in the earlier .... 路 17 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 17 Nov 2026
- AstraZeneca Pharma India Limited has informed the Exchange about General Updates 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 06 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 05 Nov 2026
- AstraZeneca Pharma India Limited has informed the Exchange about Appointment/ Change in designation of Senior Management Personnel 路 05 Nov 2026
- Please find the enclosed intimation of the Company as per the captioned subject for your reference. 路 05 Nov 2026
